Maze Therapeutics appoints Paula Johnson and Sophie Kornowski to board of directors
Maze Therapeutics named two new non-employee directors, Paula Johnson and Sophie Kornowski, effective August 13, 2026, and announced the appointments in a press release that day. The Board also reassigned two existing directors to different classes so that each class has roughly one-third of the Board, as its certificate of incorporation contemplates.
Key points
- Paula A. Johnson, M.D., M.P.H., joined as a Class III director with a term expiring at the 2028 annual meeting and was added to the nominating and corporate governance committee.
- Sophie Kornowski, Pharm.D., joined as a Class I director with a term expiring at the 2029 annual meeting and was added to the audit and compensation committees.
- Each new director receives a pro rata share of the $40,000 annual cash retainer and an option to purchase 36,000 shares of common stock, vesting monthly from the appointment date.
- Nancy C. Andrews and Hervé Hoppenot resigned and were immediately reappointed to Class II and Class III, respectively.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.